Singapore, Aug. 1 -- CREATE Medicines, Inc., a US-based clinical-stage biotechnology company pioneering in vivo immune programming, has announced a strategic research collaboration with Australia's Monash University and its world-leading Monash Institute of Pharmaceutical Sciences (MIPS).

The partnership broadens CREATE's portfolio by accessing Monash's advanced lipid nanoparticle (LNP) technology including proprietary binders and chemistry, strengthening its leadership in developing best-in-class targeted in vivo therapies.

Targeted delivery remains one of the primary challenges in realising the full therapeutic potential of in vivo cell therapies, requiring increasingly precise control over which immune cells receive therapeutic paylo...